Skip to main content
Clinical Trials/EUCTR2009-015007-97-IT
EUCTR2009-015007-97-IT
Active, not recruiting
Phase 1

Retinal Nerve Fiber Layer (RNFL) as measured by Optical Coherence Tomography (OCT) to Depict axonal loss in Early RRMS treated with difFEreNt dosage of subCutaneous IFN bEta 1a - DEFENCE

DR. ENRICO MONTANARI0 sites144 target enrollmentOctober 1, 2009

Overview

Phase
Phase 1
Intervention
Not specified
Conditions
Patients with RR-MS diagnosis
Sponsor
DR. ENRICO MONTANARI
Enrollment
144
Status
Active, not recruiting
Last Updated
9 years ago

Overview

Brief Summary

No summary available.

Registry
who.int
Start Date
October 1, 2009
End Date
TBD
Last Updated
9 years ago
Study Type
Interventional clinical trial of medicinal product
Sex
All

Investigators

Sponsor
DR. ENRICO MONTANARI

Eligibility Criteria

Inclusion Criteria

  • oRR\-MS diagnosis according to the revised Mc Donald criteria
  • oRRMS diagnosis within 2 years
  • oPatients of both sexes, aged 18\-50 years
  • oPatients DMDs treatment na?ve
  • oPatients valid informed consent to take part in the study.
  • Are the trial subjects under 18? no
  • Number of subjects for this age range:
  • F.1\.2 Adults (18\-64 years) yes
  • F.1\.2\.1 Number of subjects for this age range
  • F.1\.3 Elderly (\>\=65 years) no

Exclusion Criteria

  • oPrimary or secondary progressive MS
  • oPatients with previous DMD treatment courses
  • oPatients receiving oral or parenteral steroid or ACTH courses within the 30 days preceding visit 1 (prior to enrolment)
  • oPatients unwilling to comply with study requirements
  • oContra\-indications for IFN\-\&\#946;1a treatment as defined in the SmPC or hypersensitivity to any components of formulation
  • oSuffer of dementia (DSM IV criteria) with a SIDAM score \<33
  • oSuffer of major medical or psychiatric illness
  • oPrevious history of NORB
  • oContra\-indications for tropicamide: patients with a narrow angle between the iris and cornea; closed angle glaucoma; hypersensitivity to tropicamide or any excipients of the formulation

Outcomes

Primary Outcomes

Not specified

Similar Trials

Recruiting
Not Applicable
Measurement of macular retinal nerve fiber layer thickness using spectral domain optical coherence tomographyGlaucome
JPRN-UMIN000002841Hiroshima University Department of Ophthalmology and Visual Science100
Not yet recruiting
Not Applicable
Measurement of retinal nerve fibre layer after vitrectomy and internal limiting membrane peeling in patients with idiopathic epiretinal membrane and macular holeH35.3Degeneration of macula and posterior pole
DRKS00004535niversitäts-Augenklinik Freiburg30
Recruiting
Not Applicable
Progressive retinal nerve fiber layer (RNFL) thinning as a biomarker to guide intraocular pressure (IOP) lowering treatment in ocular hypertensives (OHT)
ACTRN12618000453280Prof Leung Kai Shun Christopher310
Completed
Not Applicable
Retinal Nerve Fiber Layer Thickness Measurements in Patients With Sleep Apnea SyndromeObstructive Sleep ApneaHypopnea SyndromeGlaucoma
NCT01188291Carmel Medical Center166
Recruiting
Not Applicable
The Characteristic of Retinal Nerve Fiber Layer Thickness in Advance and End-stage Glaucoma using Spectral Domain Optical Coherence TomographyThis research aims to study structural changes (retinal nerve fiber layer) in patients with advance and end-stage glaucoma, by compare the characteristic of retinal nerve fiber layer thickness between advance and end-stage glaucoma using spectral domain optical coherence tomography, to find the prevention the progression of the disease from advance to end-stage glaucoma.Retinal Nerve Fiber LayerAdvance GlaucomaEnd-stage GlaucomaOptical Coherence Tomography
TCTR20230713010Faculty of Medicine Siriraj Hospital, Mahidol University80